SALT LAKE CITY, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its third quarter 2024 operating results on Wednesday, November 6, 2024, after market close. In conjunction, the company will host a conference call to review the results at 4:30 pm ET on the same day.
Conference Call Details
The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID “HCATQ324.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its clients leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
Health Catalyst Investor Relations Contact:
Jack Knight
Vice President, Investor Relations
+1 (855) 309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.
Health Catalyst Media Contact:
Amanda Flanders
Senior Vice President, Marketing and Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$8.25 |
Daily Change: | 0.49 6.31 |
Daily Volume: | 608,596 |
Market Cap: | US$498.880M |
November 06, 2024 November 06, 2024 November 06, 2024 August 27, 2024 August 08, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB